NCT07025330

A Study of Efgartigimod in Patients With IgG4-Related Disease

A Phase IIa, Single-Site, Open-Label Study of Efgartigimod in Patients With IgG4-Related Disease

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 5 (estimated)
• Sponsor: Stanford University · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if efgartigimod can treat IgG4-related disease in adults. The main questions it aims to answer are: In patients with IgG4-related disease, does treatment with efgartigimod reduce the volume of the: * lacrimal gland(s) and/or * salivary gland(s) and/or * pancreas Participants will: * Receive efgartigimod once weekly for up to 12 weeks * Visit the clinic every one to six weeks for checkups and tests * Be asked to complete questionnaires to see how they feel on efgartigimod

Conditions

• IgG4-related Disease

Interventions

Type	Name	Description
DRUG	Efgartigimod	efgartigimod 1000 mg subcutaneous injection given once weekly

Timeline

• Start date: 2025-11-12
• Primary completion: 2028-03-01
• Completion: 2028-06-01
• First posted: 2025-06-17
• Last updated: 2026-02-10

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study